Radiopharm Theranostics has finished enrolling patients in its U.S. Phase 2b trial of RAD 101 for brain metastases imaging, reporting promising interim data showing 90% concordance with MRI. The company aims to launch a pivotal Phase 3 trial following a full data readout in June 2026.
- Final patient dosed in U.S. Phase 2b RAD 101 imaging trial
- Interim results show 90% concordance with MRI, primary endpoint
- RAD 101 targets fatty acid synthase to improve brain metastases detection
- Phase 3 pivotal trial planned with FDA engagement underway
- More than 300,000 U.S. patients diagnosed annually with brain metastases
Completion of Phase 2b Marks Key Milestone for RAD 101
Radiopharm Theranostics (ASX:RAD) has reached a significant clinical milestone by completing enrollment and dosing in its U.S. Phase 2b imaging trial for RAD 101, a novel radiopharmaceutical designed to detect recurrent brain metastases. Interim data reveal a 90% concordance rate with the current diagnostic gold standard, MRI, underscoring RAD 101’s potential to enhance diagnostic accuracy in a notoriously challenging area.
With the primary endpoint readout scheduled for June 2026, Radiopharm is already preparing to advance RAD 101 into a pivotal Phase 3 trial in the U.S., signalling confidence in the molecule’s clinical promise. CEO Riccardo Canevari highlighted the importance of this progress, noting the trial’s momentum and the company’s intention to engage with the FDA to chart the optimal regulatory pathway.
Targeting Fatty Acid Synthase to Improve Imaging Precision
RAD 101 operates by targeting fatty acid synthase (FASN), an enzyme overexpressed in many solid tumors including cerebral metastases. This mechanism may provide a more precise imaging method compared to conventional contrast-enhanced MRI, which can struggle to distinguish recurrent disease from treatment effects during follow-up scans.
The Phase 2b trial involved 30 patients with confirmed recurrent brain metastases from various solid tumors. The study’s primary objective was to assess how well 18F-RAD101-positive lesions matched those detected by MRI. The FDA has granted RAD 101 Fast Track Designation, recognising the urgent need for improved diagnostic tools in this patient population, which exceeds 300,000 new cases annually in the U.S. alone.
Strategic Partnerships and Pipeline Momentum
Radiopharm’s progress with RAD 101 dovetails with its broader clinical efforts, including a recent agreement with Siemens Healthineers to supply the radiolabelled compound for the upcoming Phase 3 trial. This partnership supports a global multi-centre registrational study, reinforcing the company’s strategic positioning in oncology radiopharmaceuticals.
This momentum is echoed in Radiopharm’s other pipeline programs, such as the Phase 1 dose escalation of 177Lu-RAD202 targeting HER2-positive solid tumors, which recently received a positive safety recommendation to escalate dosing. These developments collectively signal Radiopharm’s commitment to expanding its footprint in precision oncology diagnostics and therapeutics. The company’s trajectory reflects a methodical build-up of clinical evidence across multiple indications, positioning RAD 101 as a potential game-changer in brain metastases imaging.
Bottom Line?
The June 2026 data readout will be pivotal for RAD 101’s regulatory and commercial trajectory, but questions remain on how it will compete with entrenched MRI standards and navigate FDA approval.
Questions in the middle?
- Will RAD 101’s diagnostic accuracy translate into improved patient outcomes and clinical decision-making?
- How will Radiopharm’s FDA discussions shape the design and timing of the Phase 3 pivotal trial?
- What competitive advantages does RAD 101 hold against emerging imaging technologies in brain metastases?